1-(4-bromo-2-chlorophenyl)ethanamine | 943152-99-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-bromo-2-chlorophenyl)ethanamine
• CAS: 943152-99-6
• 化学式: C₈H₉BrClN
• 分子量: 234.523
• InChiKey: HIVILXRPZVDOLD-UHFFFAOYSA-N

物化性质

• 沸点：
  285.9±25.0 °C(Predicted)
• 密度：
  1.514±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(4-bromo-2-chlorophenyl)ethanamine 在 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 N-(1-(4-bromo-2-chlorophenyl)ethyl)-3-fluoro-N-(pyridin-3-ylmethyl)benzamide
  参考文献：
  名称：

  [EN] SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1
  [FR] BENZAMIDES SUBSTITUÉS EN TANT QUE MODULATEURS DE TREX1

  摘要：

  提供的是化合物的化学式(I)及其药用盐和组合物，这些化合物对治疗与TREX1相关的各种疾病条件有用。

  公开号：

  WO2021243001A1
• 作为产物：
  描述：

  2'-氯-4'-溴苯乙酮 在 盐酸羟胺 、 溶剂黄146 、 锌 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 34.0h， 生成 1-(4-bromo-2-chlorophenyl)ethanamine
  参考文献：
  名称：

  [EN] SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1
  [FR] BENZAMIDES SUBSTITUÉS EN TANT QUE MODULATEURS DE TREX1

  摘要：

  提供的是化合物的化学式(I)及其药用盐和组合物，这些化合物对治疗与TREX1相关的各种疾病条件有用。

  公开号：

  WO2021243001A1

文献信息

• Compounds with medicinal effects due to interaction with the glucocorticoid receptor
  申请人：Hamilton Morton Niall

  公开号：US20070149577A1

  公开（公告）日：2007-06-28

  The invention provides for compounds having the structure according to the formula I wherein: X is a carbon or nitrogen atom; Ar is phenyl or heteroaromatic ring; R 1 is hydrogen, halogen, CN or (1C-4C)alkyl; R 2 is hydrogen, halogen or optionally fluorinated (1C-3C)alkoxy; R 3 and R 5 are independently hydrogen, optionally halogenated (1C-4C)alkyl, optionally halogenated (1C-4C)alkoxy, optionally halogenated aryl(1C-4C)alkoxy, optionally halogenated (1C-4C)alkenyl or hydroxylmethyl; R 4 is hydrogen, halogen, optionally halogenated (1C-4C)alkoxy or optionally halogenated aryl(1C-4C)alkoxy; R 6 is hydrogen, benzyl, optionally substituted with one or more halogens or (1C-4C)alkyl, or R 6 is optionally halogenated (1C-4C)alkyl; each R 7 independently is hydrogen, halogen, optionally halogenated (1C-4C)alkyl or optionally halogenated (1C-4C)alkoxy and pharmaceutically suitable acid addition salts thereof for use as glucocorticoid receptor modulators, in particular for treatment of central nervous system disorders.

  该发明提供了具有以下结构的化合物，符合以下式I的结构：其中：X是碳或氮原子；Ar是苯基或杂环芳香环；R1是氢、卤素、CN或(1C-4C)烷基；R2是氢、卤素或可选氟化的(1C-3C)烷氧基；R3和R5分别是氢、可选卤代的(1C-4C)烷基、可选卤代的(1C-4C)烷氧基、可选卤代的芳基(1C-4C)烷氧基、可选卤代的(1C-4C)烯基或羟甲基；R4是氢、卤素、可选卤代的(1C-4C)烷氧基或可选卤代的芳基(1C-4C)烷氧基；R6是氢、苄基，可选用一个或多个卤素或(1C-4C)烷基取代，或R6是可选卤代的(1C-4C)烷基；每个R7独立地是氢、卤素、可选卤代的(1C-4C)烷基或可选卤代的(1C-4C)烷氧基，以及其药用合适的酸盐，用作糖皮质激素受体调节剂，特别用于治疗中枢神经系统疾病。
• Fused heterocyclic derivatives and methods of use
  申请人：Albrecht Brian K.

  公开号：US20090124612A1

  公开（公告）日：2009-05-14

  Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于预防和治疗疾病，如HGF介导的疾病具有有效性。本发明包括新颖的化合物、类似物、前药和其药学上可接受的盐、药物组合物和预防和治疗涉及癌症等疾病和其他疾病或病况的方法。该发明还涉及制备这样的化合物的过程，以及在这样的过程中有用的中间体。
• Nitrogen-Containing heterocyclyl ketones and methods of use
  申请人：Albrecht Brian K.

  公开号：US20080280917A1

  公开（公告）日：2008-11-13

  Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于预防和治疗HGF介导的疾病等疾病有效。本发明涵盖了新型化合物、类似物、前药和其药学上可接受的盐、制药组合物以及预防和治疗涉及癌症等疾病和其他疾病或病况的方法。本发明还涉及制造这种化合物的过程，以及在这些过程中有用的中间体。
• FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE
  申请人：ALBRECHT Brian K.

  公开号：US20120148531A1

  公开（公告）日：2012-06-14

  Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的化合物对于预防和治疗疾病，如HGF介导的疾病，具有有效性。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的盐、制药组合物以及用于预防和治疗涉及癌症等疾病和其他疾病或病情的方法。该发明还涉及制备这种化合物的过程以及在这种过程中有用的中间体。
• [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR
  申请人：Amgen, Inc

  公开号：EP3093289A1

  公开（公告）日：2016-11-16

  Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物可有效预防和治疗疾病，如 HGF 介导的疾病。本发明包括新型化合物、类似物、原药及其药学上可接受的盐、药物组合物以及用于预防和治疗涉及癌症等疾病和其他弊病或病症的方法。本发明还涉及制造此类化合物的工艺以及在此类工艺中有用的中间体。